— Know what they know.
Not Investment Advice

PCRX NASDAQ

Pacira BioSciences, Inc.
1W: -0.2% 1M: -5.6% 3M: +1.1% YTD: -4.0% 1Y: -12.2% 3Y: -43.1% 5Y: -62.3%
$23.35
-0.13 (-0.55%)
 
Weekly Expected Move ±5.1%
$20 $21 $23 $24 $25
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Alpha Radar Sell · Power 43 · $918.5M mcap · 38M float · 1.90% daily turnover · Short 48% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NARROW EDGE
59.3 / 100
NoneWeakNarrowWide
Primary source: Intangible Assets  ·  ROIC: 1.0%  ·  5Y Avg: 0.2%
Cost Advantage
59
Intangibles
73
Switching Cost
64
Network Effect
48
Scale
40
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. PCRX has a Narrow competitive edge (59.3/100) — meaningful but not impregnable advantages over competitors. The primary source of advantage is Intangible Assets. ROIC of 1.0% suggests modest returns relative to capital deployed.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$32
Low
$32
Avg Target
$32
High
Based on 1 analyst since Apr 30, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 15Hold: 17Sell: 4Strong Sell: 0
Rating Summary
ConsensusHold
Avg Target$32.00
Analysts1
Consensus Change History
DateFieldFromTo
2026-03-27 consensus Buy Hold
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-01 Needham $63 $32 -31 +25.5% $25.49
2025-12-08 Barclays $24 $27 +3 +10.6% $24.42
2025-02-28 Barclays Initiated $24 -0.2% $24.05
2025-02-28 H.C. Wainwright $57 $48 -9 +99.6% $24.05
2025-01-30 Truist Financial Les Sulewski $8 $25 +17 -4.0% $26.03
2024-11-07 Piper Sandler David Amsellem $42 $12 -30 -30.9% $17.36
2024-09-24 Jefferies Glen Santangelo $36 $18 -18 +21.9% $14.77
2024-08-13 Truist Financial Les Sulewski Initiated $8 -34.9% $12.29
2024-07-02 H.C. Wainwright Oren Livnat Initiated $57 +160.2% $21.91
2024-06-13 Jefferies Glen Santangelo Initiated $36 +26.3% $28.50
2024-05-21 Piper Sandler David Amsellem Initiated $42 +36.9% $30.68
2023-01-06 BMO Capital Initiated $52 +35.1% $38.50
2023-01-06 Needham Initiated $63 +63.6% $38.50

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

B+
May 22, 2026
DCF
5
ROE
3
ROA
4
D/E
1
P/E
1
P/B
4
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. PCRX receives an overall rating of B+. Strongest factors: DCF (5/5), ROA (4/5), P/B (4/5). Areas of concern: D/E (1/5), P/E (1/5).
Rating Change History
DateFromTo
2026-05-14 B B+
2026-05-04 B+ B
2026-04-30 B B+
2026-03-03 B+ B
2026-02-26 B B+
2026-01-12 A- B

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

46 Grade B
Profitability
24
Balance Sheet
68
Earnings Quality
64
Growth
59
Value
53
Momentum
88
Safety
30
Cash Flow
61
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. PCRX scores highest in Momentum (88/100) and lowest in Profitability (24/100). A grade of B indicates above-average fundamentals with room for improvement in select areas.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
1.81
Distress Zone
Piotroski F-Score
7/9
Beneish M-Score
-2.94
Unlikely Manipulator
Ohlson O-Score
-8.58
Bankruptcy prob: 0.0%
Low Risk
Credit Rating
BB+
Score: 49.2/100
Trend: Improving
Earnings Quality
75/100
OCF/NI: 27.68x
Accruals: -9.7%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. PCRX scores 1.81, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. PCRX scores 7/9, signaling strong financial health across all three dimensions. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. PCRX's score of -2.94 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. PCRX's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. PCRX receives an estimated rating of BB+ (score: 49.2/100), with a improving trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). PCRX's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
183.88x
PEG
-3.25x
P/S
1.25x
P/B
1.44x
P/FCF
6.97x
P/OCF
6.50x
EV/EBITDA
9.63x
EV/Revenue
1.55x
EV/EBIT
41.91x
EV/FCF
8.59x
Earnings Yield
0.56%
FCF Yield
14.35%
Shareholder Yield
21.46%
Graham Number
$6.92
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 183.9x earnings, PCRX is priced for high growth expectations. Graham's intrinsic value formula yields $6.92 per share, 237% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.390
NI / EBT
×
Interest Burden
0.484
EBT / EBIT
×
EBIT Margin
0.037
EBIT / Rev
×
Asset Turnover
0.521
Rev / Assets
×
Equity Multiplier
1.915
Assets / Equity
=
ROE
0.7%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. PCRX's ROE of 0.7% is driven by Asset Turnover (0.521), indicating efficient use of assets to generate revenue. A tax burden ratio of 0.39 suggests the company retains less than 60% of pre-tax earnings after taxes.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
$1.07
Price/Value
21.17x
Margin of Safety
-2017.02%
Premium
2017.02%
Assessment
Overvalued
Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with PCRX's realized 0.0% 3-year EPS CAGR — what the company actually delivered, not what analysts hope for. PCRX trades at a 2017% premium to its adjusted intrinsic value of $1.07, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 8.5x compares to the current market P/E of 183.9x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$23.35
Median 1Y
$19.44
5th Pctile
$9.25
95th Pctile
$41.38
Ann. Volatility
48.2%
Analyst Target
$32.00
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Frank Lee
Chief Executive Officer
$896,539 $3,184,640 $15,944,347
Kristen Williams Administrative
rative Officer and Secretary
$519,262 $2,606,742 $3,609,174
Daryl Gaugler President,
Vice President, Commercial Operations
$511,808 $2,606,742 $3,593,706
Jonathan Slonin Medical
edical Officer
$535,000 $1,717,324 $2,878,928
Shawn Cross Financial
ancial Officer
$100,962 $1,242,750 $2,743,225
Lauren Riker Interim
Interim Chief Financial Officer
$374,560 $612,605 $1,438,907
Charles A. Reinhart,
III Former Chief Financial Officer
$374,173 $350,470 $1,284,544
David Stack
Former Chief Executive Officer
$634,038 $— $727,378

CEO Pay Ratio

36:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $15,944,347
Avg Employee Cost (SGA/emp): $444,824
Employees: 829

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
829
+4.9% YoY
Revenue / Employee
$876,250
Rev: $726,411,000
Profit / Employee
$8,485
NI: $7,034,000
SGA / Employee
$444,824
Avg labor cost proxy
R&D / Employee
$141,510
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE 35.7% 12.6% 6.2% 5.7% 5.8% 3.1% 2.1% -1.4% -0.6% 0.9% 5.1% 8.6% 7.7% -11.0% -12.1% -12.6% -15.5% 2.6% 1.0% 0.7% 0.70%
ROA 16.5% 5.9% 2.5% 2.3% 2.3% 1.2% 0.8% -0.6% -0.2% 0.4% 2.6% 4.3% 3.9% -5.6% -6.4% -6.6% -8.1% 1.4% 0.5% 0.4% 0.36%
ROIC 43.2% 13.4% 5.6% 5.5% 5.8% 5.1% 5.7% 2.5% 3.0% 2.5% 5.1% 6.1% 5.0% -4.4% -6.2% -7.2% -8.8% 2.3% 0.9% 1.0% 0.97%
ROCE 8.1% 9.9% 5.5% 5.3% 5.2% 3.9% 3.2% 1.0% 1.7% 2.2% 5.3% 7.7% 7.6% -2.9% -4.0% -4.3% -7.3% 4.6% 2.8% 2.4% 2.38%
Gross Margin 74.0% 72.9% 75.5% 77.2% 70.1% 69.7% 64.0% 69.4% 71.6% 75.8% 73.7% 71.6% 75.1% 76.9% 78.7% 79.7% 77.4% 80.9% 79.5% 79.5% 79.47%
Operating Margin 25.7% 24.6% 2.6% 11.0% 18.4% 12.7% -5.8% -1.9% 23.5% 10.8% 18.3% 7.9% 15.9% -82.8% 13.2% 1.2% 4.7% 3.5% 1.6% 2.6% 2.61%
Net Margin 14.1% 13.8% -3.2% 4.3% 11.7% -0.4% -5.9% -12.2% 15.2% 6.6% 13.7% 5.4% 10.6% -85.1% 8.6% 2.8% -2.7% 3.0% 0.8% 1.6% 1.64%
EBITDA Margin 27.2% 28.7% 10.4% 23.0% 30.0% 18.6% 12.8% 1.1% 35.5% 23.1% 30.3% 20.8% 32.9% -68.1% 27.0% 19.9% 16.1% 19.1% 12.8% 16.6% 16.64%
FCF Margin 16.5% 19.1% 14.7% 17.9% 16.7% 14.2% 17.3% 15.6% 18.9% 19.6% 20.7% 25.4% 26.8% 27.8% 25.5% 22.7% 16.6% 17.3% 18.8% 18.1% 18.06%
OCF Margin 25.6% 29.1% 23.2% 24.9% 23.5% 19.3% 21.8% 20.0% 22.0% 22.4% 22.9% 27.1% 28.2% 29.3% 27.0% 25.0% 19.1% 19.7% 20.9% 19.4% 19.35%
ROE 3Y Avg snapshot only -1.50%
ROE 5Y Avg snapshot only -0.11%
ROA 3Y Avg snapshot only -0.60%
ROIC 3Y Avg snapshot only -0.04%
ROIC Economic snapshot only 0.78%
Cash ROA snapshot only 11.24%
Cash ROIC snapshot only 15.64%
CROIC snapshot only 14.60%
NOPAT Margin snapshot only 1.20%
Pretax Margin snapshot only 1.79%
R&D / Revenue snapshot only 16.29%
SGA / Revenue snapshot only 51.16%
SBC / Revenue snapshot only 7.69%
Valuation
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio 15.89 41.31 63.92 92.20 77.98 116.74 111.35 -179.36 -456.61 228.76 41.87 21.64 22.74 -7.65 -9.28 -11.15 -8.52 53.44 158.14 179.95 183.878
P/S Ratio 5.50 4.96 4.95 6.11 4.98 3.73 2.66 2.80 3.12 2.40 2.60 2.24 2.09 1.00 1.32 1.65 1.54 1.60 1.53 1.26 1.250
P/B Ratio 4.46 4.11 3.67 4.85 4.19 3.34 2.29 2.42 2.69 2.06 2.02 1.75 1.66 0.80 1.19 1.49 1.40 1.47 1.60 1.33 1.445
P/FCF 33.38 25.96 33.60 34.09 29.87 26.30 15.38 17.92 16.47 12.26 12.59 8.81 7.83 3.59 5.17 7.25 9.28 9.22 8.14 6.97 6.967
P/OCF 21.50 17.07 21.34 24.54 21.23 19.28 12.19 14.03 14.16 10.71 11.36 8.26 7.44 3.41 4.88 6.58 8.08 8.10 7.32 6.50 6.501
EV/EBITDA 27.14 21.10 27.69 31.76 25.16 21.56 16.00 22.22 22.26 17.04 13.35 9.77 9.43 29.97 37.02 46.76 -953.66 8.79 10.84 9.63 9.633
EV/Revenue 5.54 5.00 5.83 6.92 5.75 4.45 3.37 3.51 3.83 3.11 3.06 2.69 2.54 1.44 1.54 1.86 1.76 1.81 1.83 1.55 1.552
EV/EBIT 33.64 25.38 36.95 48.56 43.78 47.87 45.96 159.91 99.41 60.74 26.12 16.20 15.69 -23.51 -21.71 -24.49 -13.59 22.85 42.20 41.91 41.908
EV/FCF 33.62 26.16 39.52 38.64 34.48 31.39 19.50 22.45 20.21 15.91 14.80 10.58 9.49 5.18 6.03 8.22 10.60 10.47 9.72 8.59 8.594
Earnings Yield 6.3% 2.4% 1.6% 1.1% 1.3% 0.9% 0.9% -0.6% -0.2% 0.4% 2.4% 4.6% 4.4% -13.1% -10.8% -9.0% -11.7% 1.9% 0.6% 0.6% 0.56%
FCF Yield 3.0% 3.9% 3.0% 2.9% 3.3% 3.8% 6.5% 5.6% 6.1% 8.2% 7.9% 11.4% 12.8% 27.9% 19.3% 13.8% 10.8% 10.8% 12.3% 14.4% 14.35%
Price/Tangible Book snapshot only 3.033
EV/OCF snapshot only 8.020
EV/Gross Profit snapshot only 1.956
Acquirers Multiple snapshot only 50.294
Shareholder Yield snapshot only 21.46%
Graham Number snapshot only $6.92
Leverage & Solvency
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 2.57 2.57 1.66 1.66 1.66 1.66 3.37 3.37 3.37 3.37 5.24 5.24 5.24 5.24 2.40 2.40 2.40 2.40 4.54 4.54 4.544
Quick Ratio 2.32 2.32 1.47 1.47 1.47 1.47 2.72 2.72 2.72 2.72 4.17 4.17 4.17 4.17 2.00 2.00 2.00 2.00 3.28 3.28 3.276
Debt/Equity 0.87 0.87 1.55 1.55 1.55 1.55 0.99 0.99 0.99 0.99 0.67 0.67 0.67 0.67 0.82 0.82 0.82 0.82 0.66 0.66 0.656
Net Debt/Equity 0.03 0.03 0.65 0.65 0.65 0.65 0.61 0.61 0.61 0.61 0.35 0.35 0.35 0.35 0.20 0.20 0.20 0.20 0.31 0.31 0.312
Debt/Assets 0.42 0.42 0.54 0.54 0.54 0.54 0.45 0.45 0.45 0.45 0.37 0.37 0.37 0.37 0.41 0.41 0.41 0.41 0.36 0.36 0.359
Debt/EBITDA 5.27 4.45 9.91 8.93 8.04 8.36 5.44 7.22 6.64 6.28 3.79 3.13 3.15 17.53 21.94 22.80 -491.05 4.32 3.71 3.84 3.838
Net Debt/EBITDA 0.19 0.16 4.15 3.74 3.37 3.50 3.38 4.49 4.13 3.90 1.99 1.64 1.65 9.20 5.30 5.50 -118.55 1.04 1.76 1.82 1.824
Interest Coverage 2.94 3.56 2.69 2.36 2.19 1.54 1.22 0.37 0.75 1.22 3.89 8.06 8.41 -2.94 -3.32 -3.30 -5.13 3.39 1.93 1.83 1.827
Equity Multiplier 2.06 2.06 2.84 2.84 2.84 2.84 2.17 2.17 2.17 2.17 1.81 1.81 1.81 1.81 2.00 2.00 2.00 2.00 1.82 1.82 1.825
Cash Ratio snapshot only 1.977
Debt Service Coverage snapshot only 7.947
Cash to Debt snapshot only 0.525
FCF to Debt snapshot only 0.292
Defensive Interval snapshot only 236.1 days
Efficiency & Turnover
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 0.48 0.49 0.32 0.35 0.37 0.39 0.36 0.36 0.36 0.35 0.41 0.42 0.42 0.43 0.45 0.45 0.45 0.46 0.52 0.52 0.521
Inventory Turnover 2.15 2.22 1.72 1.78 1.97 2.16 2.05 2.18 2.16 2.04 1.84 1.83 1.79 1.78 1.48 1.37 1.34 1.30 1.08 1.09 1.092
Receivables Turnover 10.00 10.21 7.25 7.77 8.23 8.76 6.85 6.87 6.87 6.84 6.62 6.69 6.77 6.81 6.41 6.42 6.45 6.55 6.12 6.19 6.192
Payables Turnover 11.35 11.76 13.37 13.82 15.29 16.82 15.47 16.48 16.29 15.44 11.95 11.84 11.59 11.53 9.79 9.03 8.84 8.57 8.74 8.86 8.859
DSO 36 36 50 47 44 42 53 53 53 53 55 55 54 54 57 57 57 56 60 59 59.0 days
DIO 170 164 212 205 186 169 178 167 169 179 198 200 204 205 246 266 272 281 339 334 334.3 days
DPO 32 31 27 26 24 22 24 22 22 24 31 31 32 32 37 40 41 43 42 41 41.2 days
Cash Conversion Cycle 174 169 235 226 206 189 208 198 200 208 223 224 227 227 266 283 288 294 357 352 352.0 days
Fixed Asset Turnover snapshot only 4.027
Operating Cycle snapshot only 393.2 days
Cash Velocity snapshot only 3.082
Capital Intensity snapshot only 1.721
Growth (YoY)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 23.2% 21.9% 26.0% 31.0% 22.1% 27.4% 23.1% 15.3% 8.9% 1.8% 1.2% 1.9% 3.2% 4.4% 3.9% 3.1% 2.3% 3.1% 3.6% 4.6% 4.57%
Net Income 18.3% -51.1% -71.2% -74.0% -77.5% -66.1% -62.1% -1.3% -1.1% -66.6% 1.6% 7.7% 14.9% -14.0% -3.4% -2.5% -3.0% 1.2% 1.1% 1.0% 1.05%
EPS 17.0% -52.4% -71.1% -74.2% -80.4% -66.4% -63.2% -1.3% -1.1% -70.6% 1.3% 6.9% 15.3% -15.7% -3.5% -2.7% -3.2% 1.2% 1.1% 1.1% 1.06%
FCF 5.3% 2.5% 1.0% 1.7% 23.6% -5.5% 44.3% 0.7% 23.7% 40.5% 21.1% 65.5% 45.8% 48.6% 28.1% -8.0% -36.6% -35.8% -23.5% -16.7% -16.75%
EBITDA 1.5% 1.6% 79.4% 84.7% 36.7% 11.0% 23.2% -16.4% -18.1% -9.9% 10.1% 77.3% 61.7% -72.5% -81.2% -85.1% -1.0% 3.4% 3.2% 3.2% 3.22%
Op. Income 5.4% 2.6% 94.0% 80.5% -7.1% -29.1% -33.3% -55.0% -42.8% -39.8% 46.1% 1.6% 91.7% -2.5% -1.8% -1.8% -2.1% 1.6% 1.3% 1.3% 1.27%
OCF Growth snapshot only -19.08%
Asset Growth snapshot only -18.58%
Equity Growth snapshot only -10.95%
Debt Growth snapshot only -28.88%
Shares Change snapshot only -12.07%
Growth (CAGR)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 3Y 18.1% 16.9% 17.1% 17.9% 18.1% 18.4% 16.6% 15.4% 17.9% 16.5% 16.2% 15.5% 11.1% 10.6% 9.0% 6.6% 4.7% 3.1% 2.9% 3.2% 3.17%
Revenue 5Y 13.5% 13.5% 14.4% 15.7% 16.9% 18.5% 18.4% 18.0% 17.0% 15.7% 14.9% 14.0% 13.1% 12.0% 10.7% 10.0% 11.6% 11.2% 11.1% 10.7% 10.65%
EPS 3Y 66.2% 60.9% 1.1% -63.9% -37.2% -25.1% -30.9% 1.9% -22.1%
EPS 5Y 49.6% 47.6% -29.9% -45.0% -47.7% -47.71%
Net Income 3Y 72.9% 72.8% 1.1% -61.9% -33.9% -21.9% -28.5% 0.9% -23.8%
Net Income 5Y 56.8% 52.9% -29.8% -45.4% -48.9% -48.92%
EBITDA 3Y 66.0% 59.5% 48.7% 42.3% 46.2% 40.7% 55.3% 28.4% 41.3% 37.8% 34.5% 39.9% 21.9% -35.0% -36.5% -39.5% 3.1% -4.4% 3.8% 3.83%
EBITDA 5Y 80.9% 1.6% 38.6% 32.3% 34.8% 33.7% 32.9% -7.2% -4.9% -10.9% 26.1% 14.0% 11.6% 11.58%
Gross Profit 3Y 18.7% 16.7% 17.0% 18.4% 17.9% 17.4% 14.2% 11.9% 15.0% 15.0% 16.2% 15.5% 11.3% 11.1% 9.8% 7.8% 6.7% 5.9% 7.2% 8.5% 8.46%
Gross Profit 5Y 14.6% 17.7% 19.3% 21.3% 22.2% 20.2% 18.7% 17.3% 15.7% 14.5% 14.4% 13.7% 13.0% 11.9% 11.0% 10.8% 12.8% 13.1% 13.0% 12.5% 12.46%
Op. Income 3Y 1.7% 1.1% 78.1% 54.3% 54.9% 52.2% 78.9% 14.3% 50.7% 15.1% 23.7% 28.8% 0.6% -17.5% -30.6% -16.9% -16.92%
Op. Income 5Y 60.7% 29.8% 40.7% 34.2% 32.4% 7.3% -15.4% -14.2% -14.17%
FCF 3Y 1.3% 53.3% 32.5% 33.5% 24.3% 17.0% 24.0% 21.5% 1.1% 66.2% 52.6% 64.7% 30.6% 25.4% 30.8% 15.3% 4.5% 10.2% 5.9% 8.2% 8.24%
FCF 5Y 87.9% 55.6% 46.7% 46.6% 79.3% 36.8% 32.3% 31.7% 28.2% 27.3% 24.3% 22.3% 54.9% 34.3% 28.4% 27.9% 27.91%
OCF 3Y 72.3% 49.6% 37.0% 37.9% 31.0% 24.3% 27.2% 22.2% 61.7% 38.4% 26.2% 30.6% 14.7% 11.0% 14.6% 6.8% -2.3% 3.8% 1.5% 2.1% 2.10%
OCF 5Y 39.6% 35.1% 30.3% 31.6% 34.5% 47.4% 52.2% 54.7% 42.4% 27.3% 25.9% 27.4% 24.8% 25.4% 21.8% 19.1% 31.0% 20.2% 14.6% 11.4% 11.40%
Assets 3Y 26.6% 26.6% 44.4% 44.4% 44.4% 44.4% 26.5% 26.5% 26.5% 26.5% 7.3% 7.3% 7.3% 7.3% -9.2% -9.2% -9.2% -9.2% -9.0% -9.0% -9.05%
Assets 5Y 26.7% 26.7% 39.6% 39.6% 39.6% 39.6% 21.8% 21.8% 21.8% 21.8% 18.0% 18.0% 18.0% 18.0% 13.3% 13.3% 13.3% 13.3% -0.2% -0.2% -0.15%
Equity 3Y 30.4% 30.4% 31.5% 31.5% 31.5% 31.5% 29.7% 29.7% 29.7% 29.7% 12.0% 12.0% 12.0% 12.0% 2.1% 2.1% 2.1% 2.1% -3.7% -3.7% -3.65%
Book Value 3Y 26.6% 26.0% 29.1% 26.4% 22.4% 27.4% 25.7% 26.7% 21.0% 22.9% 6.5% 7.3% 8.2% 11.4% -1.0% 2.1% 7.1% 3.2% -1.5% 0.1% 0.15%
Dividend 3Y
Growth Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 0.92 0.94 0.93 0.92 0.94 0.93 0.94 0.95 0.98 0.95 0.95 0.95 0.97 0.93 0.92 0.92 0.88 0.84 0.83 0.84 0.840
Earnings Stability 0.52 0.68 0.52 0.56 0.48 0.35 0.22 0.09 0.05 0.00 0.03 0.02 0.02 0.41 0.27 0.25 0.27 0.56 0.55 0.45 0.451
Margin Stability 0.98 0.92 0.91 0.90 0.91 0.96 0.97 0.96 0.97 0.98 0.98 0.96 0.97 0.97 0.97 0.95 0.95 0.96 0.95 0.94 0.942
Rev. Growth Consistency 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Earn. Growth Consistency 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.500
FCF Positive Streak 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Earnings Persistence 0.20 0.50 0.50 0.50 0.50 0.50 0.50 0.20 0.20 0.50 0.50 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.200
Earnings Smoothness 0.31 0.00 0.00 0.00 0.01 0.10 0.00 0.10
ROE Trend 0.28 -0.08 -0.04 -0.07 -0.07 -0.20 -0.13 -0.16 -0.17 -0.06 0.01 0.06 0.05 -0.12 -0.16 -0.17 -0.20 0.08 0.05 0.03 0.034
Gross Margin Trend -0.00 -0.01 0.00 0.01 0.00 -0.00 -0.03 -0.06 -0.05 -0.03 0.01 0.01 0.03 0.03 0.04 0.07 0.07 0.07 0.05 0.04 0.040
FCF Margin Trend 0.08 0.08 0.03 0.07 0.07 0.01 0.05 0.02 0.02 0.03 0.05 0.09 0.09 0.11 0.07 0.02 -0.06 -0.06 -0.04 -0.06 -0.060
Sustainable Growth Rate 35.7% 12.6% 6.2% 5.7% 5.8% 3.1% 2.1% 0.9% 5.1% 8.6% 7.7% 2.6% 1.0% 0.7% 0.70%
Internal Growth Rate 19.8% 6.2% 2.6% 2.3% 2.4% 1.3% 0.9% 0.4% 2.6% 4.5% 4.1% 1.4% 0.5% 0.4% 0.37%
Cash Flow Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income 0.74 2.42 2.99 3.76 3.67 6.06 9.13 -12.78 -32.25 21.35 3.69 2.62 3.06 -2.25 -1.90 -1.69 -1.06 6.60 21.61 27.68 27.679
FCF/OCF 0.64 0.66 0.64 0.72 0.71 0.73 0.79 0.78 0.86 0.87 0.90 0.94 0.95 0.95 0.94 0.91 0.87 0.88 0.90 0.93 0.933
FCF/Net Income snapshot only 25.828
OCF/EBITDA snapshot only 1.201
CapEx/Revenue 9.1% 10.0% 8.5% 7.0% 6.8% 5.2% 4.5% 4.3% 3.1% 2.8% 2.2% 1.7% 1.4% 1.5% 1.5% 2.3% 2.5% 2.4% 2.1% 1.3% 1.29%
CapEx/Depreciation snapshot only 0.104
Accruals Ratio 0.04 -0.08 -0.05 -0.06 -0.06 -0.06 -0.07 -0.08 -0.08 -0.08 -0.07 -0.07 -0.08 -0.18 -0.18 -0.18 -0.17 -0.08 -0.10 -0.10 -0.097
Sloan Accruals snapshot only -0.070
Cash Flow Adequacy snapshot only 14.956
Earnings Quality Score snapshot only 0.750
Dividends & Buybacks
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
FCF Payout Ratio 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Total Payout Ratio 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 39.3% 4.7% 21.1% 38.6% 38.61%
Div. Increase Streak
Chowder Number
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.7% 3.6% 2.7% 2.2% 4.6% 8.7% 13.3% 21.5% 21.46%
Net Buyback Yield -1.1% 0.0% -0.2% -0.2% -0.2% -0.2% 0.0% -0.0% -0.0% -0.0% -0.0% 0.0% 1.6% 3.4% 2.6% 2.0% 4.5% 8.6% 13.0% 21.3% 21.34%
Total Shareholder Return -1.1% 0.0% -0.2% -0.2% -0.2% -0.2% 0.0% -0.0% -0.0% -0.0% -0.0% 0.0% 1.6% 3.4% 2.6% 2.0% 4.5% 8.6% 13.0% 21.3% 21.34%
DuPont Factors
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) 3.04 0.82 0.74 0.75 0.83 0.83 1.20 0.51 0.99 0.70 0.68 0.69 0.63 1.65 1.58 1.52 1.20 0.51 0.42 0.39 0.390
Interest Burden (EBT/EBIT) 0.69 0.75 0.66 0.62 0.59 0.41 0.27 -1.39 -0.18 0.29 0.78 0.90 0.90 1.29 1.27 1.27 1.17 0.74 0.54 0.48 0.484
EBIT Margin 0.16 0.20 0.16 0.14 0.13 0.09 0.07 0.02 0.04 0.05 0.12 0.17 0.16 -0.06 -0.07 -0.08 -0.13 0.08 0.04 0.04 0.037
Asset Turnover 0.48 0.49 0.32 0.35 0.37 0.39 0.36 0.36 0.36 0.35 0.41 0.42 0.42 0.43 0.45 0.45 0.45 0.46 0.52 0.52 0.521
Equity Multiplier 2.16 2.16 2.48 2.48 2.48 2.48 2.50 2.50 2.50 2.50 1.98 1.98 1.98 1.98 1.90 1.90 1.90 1.90 1.92 1.92 1.915
Per Share
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $3.82 $1.36 $0.94 $0.83 $0.75 $0.46 $0.35 $-0.23 $-0.09 $0.13 $0.81 $1.35 $1.26 $-1.97 $-2.03 $-2.23 $-2.80 $0.48 $0.16 $0.13 $0.13
Book Value/Share $13.59 $13.63 $16.38 $15.73 $13.92 $15.94 $16.89 $16.87 $14.89 $14.88 $16.71 $16.67 $17.22 $18.86 $15.87 $16.73 $17.12 $17.51 $16.13 $16.94 $16.16
Tangible Book/Share $9.29 $9.32 $-0.87 $-0.83 $-0.74 $-0.85 $1.55 $1.55 $1.37 $1.37 $4.30 $4.28 $4.42 $4.85 $7.19 $7.57 $7.75 $7.93 $7.09 $7.45 $7.45
Revenue/Share $11.03 $11.29 $12.14 $12.50 $11.71 $14.27 $14.53 $14.56 $12.86 $12.79 $12.96 $13.06 $13.66 $15.06 $14.29 $15.10 $15.53 $16.12 $16.90 $17.96 $18.16
FCF/Share $1.82 $2.16 $1.79 $2.24 $1.95 $2.02 $2.51 $2.28 $2.43 $2.50 $2.68 $3.32 $3.66 $4.19 $3.65 $3.43 $2.58 $2.79 $3.18 $3.24 $3.28
OCF/Share $2.82 $3.28 $2.82 $3.11 $2.75 $2.76 $3.17 $2.91 $2.83 $2.86 $2.97 $3.54 $3.85 $4.42 $3.86 $3.78 $2.96 $3.18 $3.54 $3.48 $3.51
Cash/Share $11.44 $11.47 $14.72 $14.14 $12.51 $14.32 $6.29 $6.28 $5.55 $5.54 $5.35 $5.34 $5.51 $6.04 $9.88 $10.42 $10.66 $10.90 $5.55 $5.83 $5.00
EBITDA/Share $2.25 $2.67 $2.56 $2.72 $2.67 $2.94 $3.06 $2.30 $2.21 $2.34 $2.97 $3.59 $3.68 $0.72 $0.59 $0.60 $-0.03 $3.32 $2.85 $2.89 $2.89
Debt/Share $11.87 $11.90 $25.31 $24.31 $21.51 $24.63 $16.64 $16.61 $14.67 $14.66 $11.26 $11.23 $11.60 $12.70 $13.03 $13.73 $14.05 $14.37 $10.57 $11.11 $11.11
Net Debt/Share $0.43 $0.43 $10.59 $10.17 $9.00 $10.31 $10.35 $10.33 $9.12 $9.12 $5.91 $5.89 $6.08 $6.66 $3.15 $3.32 $3.39 $3.47 $5.02 $5.28 $5.28
Academic Models
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score 1.807
Altman Z-Prime snapshot only 3.545
Piotroski F-Score 5 4 6 5 4 4 5 5 6 6 7 7 8 6 5 5 5 7 8 7 7
Beneish M-Score -1.82 -2.56 -1.71 -1.82 -1.76 -1.77 -2.74 -2.81 -2.88 -2.91 -2.86 -2.81 -2.87 -3.35 -3.46 -3.46 -3.38 -2.95 -3.01 -2.94 -2.938
Ohlson O-Score snapshot only -8.576
ROIC (Greenblatt) snapshot only 4.46%
Net-Net WC snapshot only $-0.58
EVA snapshot only $-82057055.01
Credit
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only BB+
Credit Score 60.10 66.99 36.41 43.27 43.52 35.51 44.19 40.09 46.01 42.54 61.32 68.48 69.50 33.35 35.94 35.79 42.63 49.57 56.65 49.18 49.183
Credit Grade snapshot only 11
Credit Trend snapshot only 13.390
Implied Spread (bps) snapshot only 400.000
Industry Credit Rank snapshot only 38
Sector Credit Rank snapshot only 44

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms